A study of the drug ACT001 for DIPG and H3K27-altered high grade glioma
Original title: ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called ACT001 in people with certain brain tumors.
Who this trial is for. This trial is for people with DIPG or a high grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary with an H3K27 change. It is testing a drug called ACT001.
Where it stands. The trial is looking at how safe ACT001 is and whether it helps. The trial has not reported results. The answer is not in yet.
What this means, and what it doesn't
What it could mean: This drug is still being studied in people with these tumors. Someone who fits could ask their care team about it. The care team can say if it makes sense for them.
What it doesn't mean: This does not mean ACT001 works. A trial is a test, not a proven treatment. Being in a trial does not promise any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.